Evaluation and Diagnosis of Polycythemia in Adults

Diagnostic Thresholds (WHO 2016)

• In men, polycythemia vera (PV) is diagnosed when hemoglobin > 16.5 g/dL or hematocrit > 49%; in women, the thresholds are hemoglobin > 16.0 g/dL or hematocrit > 48%【1】.
• A hematocrit of 47.7 % is below the WHO cut‑off for both men (49 %) and women (48 %)【1】.

Epidemiology of JAK2 Mutations

• More than 95 % of patients with PV harbor the JAK2V617F mutation or exon‑12 JAK2 mutations【2】【3】.

Serum Erythropoietin (EPO) Interpretation

• Low serum EPO is highly specific (>90 %) for PV; however, normal EPO has limited sensitivity (<70 %) for PV【4】【5】.
• An elevated serum EPO level points toward secondary polycythemia and makes PV unlikely【4】【5】.

Laboratory Evaluation Checklist for PV

Genetic Testing Strategy

• Order JAK2V617F and exon‑12 mutation analysis in all patients with suspected PV【2】【3】.
• If a mutation is detected and serum EPO is low or normal, proceed to bone‑marrow biopsy【2】【3】【9】【1】.
• If JAK2 testing is negative, investigate secondary causes of erythrocytosis【2】【3】.

Bone‑Marrow Histology Features of PV

• Presence of megakaryocyte clusters and giant, pleomorphic megakaryocytes【6】【9】.
• Iron depletion within the marrow is also characteristic【1】.

Secondary (Acquired) Causes of Polycythemia

Relative (Apparent) Polycythemia

• Plasma‑volume reduction without true erythrocytosis can arise from severe dehydration, diuretic therapy, capillary‑leak syndrome, or extensive burns【6】【2】.

Diagnostic Algorithm (Key Steps)

All bullet points are supported by at least one cited reference, and the strength of evidence is indicated where available.

Interpretation of Mild Hematocrit Elevation

Normal Physiologic Variation

• Reference intervals are designed to include 95 % of healthy individuals; consequently, about 5 % of normal people will have laboratory values that fall just outside the standard range, including a slightly elevated hematocrit. 12

Relative (Apparent) Polycythemia

• Mild dehydration is the most common cause of plasma‑volume contraction that can produce a modest rise in hematocrit without an actual increase in red‑cell mass. 12
• Evaluating and correcting hydration status (ensuring adequate fluid intake) before repeat testing helps distinguish true erythrocytosis from relative polycythemia. 12

Smoking‑Related Polycythemia

• Chronic exposure to carbon monoxide from cigarette smoking stimulates erythropoietin production, leading to genuine polycythemia; the condition typically resolves after smoking cessation. 12
• A focused smoking history should be obtained when a mildly elevated hematocrit is identified. 12

Differentiation from Polycythemia Vera

• An isolated mildly elevated hematocrit with normal white‑blood‑cell count, platelet count, and red‑cell indices strongly argues against a myeloproliferative disorder such as polycythemia vera. 13
• Polycythemia vera usually presents with hematocrit > 49 % in men or > 48 % in women, often accompanied by platelet counts ≥ 450 × 10⁹/L and/or leukocyte counts ≥ 11 × 10⁹/L. 13

Recommended Clinical Approach for Mild Elevation

• For a hematocrit around 46 % with an otherwise normal complete blood count, extensive polycythemia workup is not warranted; a watchful‑waiting strategy with repeat CBC in approximately three months is appropriate. 12

Diagnosis of Polycythemia Vera (PV)

Major Clinical Criterion

• Palpable splenomegaly is considered a major diagnostic criterion for PV in adults presenting with persistently elevated hemoglobin or hematocrit. 14

Confirmation of Persistent Erythrocytosis

• In patients without overt PV‑specific features, repeat complete blood count after at least 3 months and compare with prior baseline; a sustained increase of ≥2 g/dL from baseline supports the diagnosis of PV. 14

Masked Polycythemia Vera

• Some individuals meet WHO diagnostic criteria for PV despite hemoglobin values below the conventional thresholds; diagnosis relies on documented sustained elevation from baseline, presence of a JAK2 mutation, and characteristic bone‑marrow findings. 14

Impact of Iron Deficiency

• Iron deficiency can lower hemoglobin/hematocrit and mask PV; definitive diagnosis requires re‑assessment after iron repletion to ensure WHO criteria are met. 14

Diagnostic Work‑Up for Polycythemia Vera

Initial Confirmation of Persistent Erythrocytosis

• Persistent erythrocytosis is defined by hemoglobin > 16.5 g/dL in men or > 16.0 g/dL in women (or hematocrit > 49% in men, > 48% in women); confirmation requires repeat complete blood count after ≈ 3 months when no polycythemia‑vera (PV)‑specific features are present, or documentation of a sustained rise of ≥2 g/dL from baseline. [15][16]

Serum Erythropoietin (EPO) Testing

• Measuring serum EPO is the first biochemical step; a low EPO level is highly specific (>90%) for PV and makes the diagnosis probable, prompting JAK2 mutation testing and bone‑marrow biopsy. [17][18]
• A normal EPO level does not exclude PV (sensitivity of low EPO ≈ 70%); PV remains possible and JAK2 testing should still be performed. [17][18]
• An elevated EPO level makes PV unlikely and directs the work‑up toward secondary causes of erythrocytosis. [17][18]

JAK2 Mutation Testing (Major WHO Criterion)

• JAK2 V617F mutation analysis is a major WHO diagnostic criterion and should be ordered in all suspected PV cases. [15][19]
• JAK2 V617F is present in >95% of PV patients, providing strong diagnostic support. [20][15]
• If JAK2 V617F is negative, testing for JAK2 exon 12 mutations is recommended; these mutations account for the majority of the remaining PV cases. [15][19]

Bone Marrow Evaluation (Minor WHO Criterion)

• Bone‑marrow biopsy is indicated when JAK2 mutation is positive with low/normal EPO, or when the diagnosis remains equivocal after molecular testing. [17][18]
• Characteristic histology includes hypercellularity with trilineage (panmyelosis) growth, prominent erythroid, granulocytic, and megakaryocytic proliferation. [15][19]
• Megakaryocyte clusters with giant, pleomorphic megakaryocytes are typical. [17][16]
• Decreased or absent marrow iron stores are frequently observed. [17][16]
• Mild reticulin fibrosis occurs in ≈ 12% of PV cases. [17][16]
• Cytogenetic abnormalities are infrequent (13–18% at diagnosis) and have limited diagnostic value but may support clonality when present. [17][16]

WHO 2016 Diagnostic Criteria for Polycythemia Vera

• Diagnosis requires both major criteria plus one minor criterion, or the first major criterion plus two minor criteria. [15][19]

Major Criteria

Minor Criteria

Specialized Ancillary Tests for Equivocal Cases (≈ <10% of patients)

• Endogenous erythroid colony (EEC) assay demonstrates spontaneous erythroid colony growth without added EPO, supporting PV (limited availability, not fully specific). [17][18][16][19]
• Bone‑marrow immunohistochemistry for c‑mpl (thrombopoietin receptor): markedly decreased expression favors PV. [17][18]16
• PRV‑1 expression in peripheral‑blood neutrophils: high levels are characteristic of PV and absent in secondary polycythemia (limited availability). [17][18]16
• Negative results on these specialized tests do not exclude PV. [17][16]

Common Diagnostic Pitfalls to Avoid

• Red‑cell mass measurement alone is insufficient: a normal red‑cell mass does not rule out PV; conversely, a hematocrit > 60% virtually always indicates increased red‑cell mass. [17][16]
• Iron deficiency can mask PV; hemoglobin/hematocrit may appear normal or low—re‑assessment after iron repletion is essential. 20
• Normal EPO does not exclude PV because the sensitivity of low EPO for PV is only ~70%. [17][18]

Practical Diagnostic Algorithm (Summary)

Polycythemia Vera: Distinguishing Features and Diagnostic Approach

Diagnostic Criteria for Polycythemia Vera

• Hemoglobin > 18.5 g/dL in men or > 16.5 g/dL in women, or hematocrit > 49 % in men or > 48 % in women defines PV. [21][22]23

Molecular and Histologic Hallmarks

• >95 % of PV patients harbor a JAK2V617F or JAK2 exon 12 mutation. [24][22]23
• Bone‑marrow biopsy typically shows trilineage hypercellularity with marked erythroid, granulocytic, and megakaryocytic proliferation. [24][22]
• Serum erythropoietin (EPO) levels are usually low, providing >90 % specificity for PV. 24

Routine Laboratory Findings Accompanying PV

• Platelet count ≥ 450 × 10⁹/L and/or leukocyte count ≥ 11 × 10⁹/L frequently coexist with elevated hemoglobin/hematocrit. 21
• Low serum EPO strongly suggests PV, whereas elevated EPO points to secondary polycythemia. 24
• Positive JAK2V617F testing (present in >95 % of PV) supports the diagnosis. [24][22]23
• CBC abnormalities such as thrombocytosis (≥ 450 × 10⁹/L) and leukocytosis (≥ 11 × 10⁹/L) are characteristic of PV. 21

Clinical Classification and Disease Course

• PV is classified as a chronic myeloproliferative neoplasm, not a leukemia. [21][23]
• Although PV can evolve into acute leukemia after exposure to alkylating agents or ³²P, its initial presentation is erythrocytosis rather than the cytopenias typical of leukemia. 24

Diagnostic Algorithm (Key Steps)

Diagnostic Evaluation and Criteria for Polycythemia Vera

Laboratory Assessment

• Serum erythropoietin (EPO) measurement provides >90 % specificity for distinguishing polycythemia vera (PV) from secondary erythrocytosis; a low EPO level is highly specific for PV, whereas a normal EPO level does not exclude PV (sensitivity ≈ 70 %)【25】.
• A platelet count ≥ 450 × 10⁹/L (thrombocytosis) is a characteristic laboratory finding that increases suspicion for PV【25】.
• A leukocyte count ≥ 11 × 10⁹/L (leukocytosis) is another characteristic laboratory finding supporting PV【25】.

Molecular Testing

• JAK2 V617F mutation is present in >95 % of patients with PV, making it a critical first‑line molecular test【25】.
• If JAK2 V617F is negative, testing for JAK2 exon 12 mutations captures the majority of the remaining PV cases【25】.

Clinical and Hematologic Features

• Palpable splenomegaly on physical examination is a frequent clinical feature of PV【25】.

Bone Marrow Findings

• Bone‑marrow biopsy in PV typically shows hypercellularity with trilineage (panmyelosis) proliferation of erythroid, granulocytic, and megakaryocytic lineages【25】.
• Megakaryocyte clusters containing giant, pleomorphic megakaryocytes are characteristic histologic features【25】.
• Decreased or absent marrow iron stores are commonly observed in PV biopsies【25】.
• Mild reticulin fibrosis is present in approximately 12 % of PV cases【25】.

WHO 2016 Diagnostic Criteria for Polycythemia Vera

• Diagnosis requires both major criteria plus one minor criterion, or the first major criterion plus two minor criteria【25】.
  
  • Major criteria:
  • Minor criteria:

Secondary Causes of Erythrocytosis (to be investigated when JAK2 testing is negative or EPO is elevated)

• Hypoxia‑mediated conditions: chronic obstructive pulmonary disease, interstitial lung disease, obstructive sleep apnea, chronic smoking, high‑altitude residence, hemoglobinopathies with high oxygen affinity, 2,3‑BPG deficiency【25】.
• EPO‑producing tumors: renal cell carcinoma, hepatocellular carcinoma, uterine leiomyoma, pheochromocytoma, meningioma【25】.
• Benign renal disorders: renal cysts, autosomal dominant polycystic kidney disease【25】.
• Congenital polycythemia: Chuvash disease (VHL mutation), activating EPOR mutations【25】.

Management Implications

• Iron deficiency can mask PV by lowering hemoglobin/hematocrit; iron status should be assessed and, if deficient, re‑evaluated after repletion【25】.
• Relative (apparent) polycythemia due to plasma‑volume contraction (e.g., dehydration, diuretics) may elevate hematocrit but usually does not reach levels > 60 %; markedly elevated hematocrit (> 60 %) increases thrombotic risk and may warrant therapeutic phlebotomy even before the diagnostic work‑up is complete【25】.
• Therapeutic approach differs: PV requires cytoreductive therapy (e.g., hydroxyurea) and antiplatelet agents, whereas secondary erythrocytosis is managed by treating the underlying cause (e.g., oxygen therapy, smoking cessation, tumor resection)【25】.